Exane BNP Paribas double upgraded Fevertree Drinks to Outperform from Underperform with a price target of 1,700 GBp, up from 900 GBp. The company is nearing the end of a downgrade cycle as the prospects for its fiscal 2024 earnings “look significantly brighter,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FQVTF:
